reninangiotensin
system
ra
complex
regulatori
network
consist
enzym
effector
peptid
facilit
mainten
homeostasi
sever
physiolog
process
upregul
ra
system
howev
chronic
condit
mainli
interact
ang
ii
receptor
lead
hypertens
involv
progress
diabet
nondiabet
chronic
kidney
diseas
ckd
clinic
intervent
target
ra
pathogen
action
center
use
ra
blocker
recent
propos
ra
system
could
therapeut
target
increas
ang
ii
degrad
ang
format
via
enzym
activ
monocarboxypeptidas
discov
metabol
ang
ii
remov
singl
amino
acid
phenylalanin
cterminu
peptid
result
format
ang
angiotensin
antiinflammatori
antiprolif
action
tend
counteract
proinflammatori
proprolif
effect
ang
ii
integr
membran
glycoprotein
express
larg
kidney
intestin
also
present
heart
lung
brain
ubiquit
initi
thought
fulllength
form
consist
three
structur
entiti
cytosol
transmembran
extracellular
domain
molecular
weight
kd
extracellular
domain
confer
enzymat
activ
contain
singl
catalyt
metallopeptidas
unit
share
sequenc
ident
sequenc
similar
catalyt
domain
ace
notabl
pharmacolog
ace
inhibitor
use
clinic
practic
inhibit
issu
nephrolog
dialysi
transplant
robert
et
al
show
among
patient
ckd
plasma
activ
lower
undergo
hemodialysi
end
stage
renal
diseas
esrd
compar
predialysi
patient
ckd
renal
transplant
patient
compar
histor
sampl
healthi
subject
howev
ckd
group
examin
ie
predialysi
transplant
patient
even
subject
dialysi
seem
increas
level
plasma
activ
statist
comparison
healthi
control
howev
could
done
sampl
healthi
individu
assay
concurr
present
studi
studi
show
opinion
plasma
activ
tend
increas
ckd
patient
perhap
compensatori
mechan
attenu
ang
ii
overact
time
esrd
reach
dialysi
initi
rel
defici
plasma
activ
ensu
signific
reduc
plasma
activ
dialysi
patient
mainli
involv
degrad
ang
ii
one
could
readili
specul
level
peptid
could
augment
therebi
predispos
hypertens
cardiovascular
morbid
level
ang
ii
ang
measur
studi
one
consid
predict
consequ
defici
howev
still
need
demonstr
one
also
wonder
signific
plasma
activ
sinc
mainli
tissu
enzym
level
circul
unlik
level
ace
rel
low
initi
attempt
measur
directli
plasma
healthi
individu
unsuccess
moreov
circul
enzymat
activ
also
shown
low
even
undetect
anim
physiolog
condit
interestingli
patholog
state
human
ischem
heart
diseas
heart
failur
diabet
accompani
vascular
complic
well
rodent
model
diabet
circul
activ
augment
studi
patient
connect
tissu
diseas
contrast
report
antibodi
plasma
reduc
enzymat
activ
predialysi
patient
ckd
renal
transplant
patient
compar
histor
sampl
healthi
subject
howev
ckd
group
examin
ie
predialysi
transplant
patient
even
subject
dialysi
seem
increas
level
plasma
activ
statist
comparison
healthi
control
howev
could
done
sampl
healthi
individu
assay
concurr
present
studi
studi
show
opinion
plasma
activ
tend
increas
ckd
patient
perhap
compensatori
mechan
attenu
ang
ii
overact
time
esrd
reach
dialysi
initi
rel
defici
plasma
activ
ensu
signific
reduc
plasma
activ
dialysi
patient
mainli
involv
degrad
ang
ii
one
could
readili
specul
level
peptid
could
augment
therebi
predispos
hypertens
cardiovascular
morbid
level
ang
ii
ang
measur
studi
one
consid
predict
consequ
defici
howev
still
need
demonstr
one
also
wonder
signific
plasma
activ
sinc
mainli
tissu
enzym
level
circul
unlik
level
ace
rel
low
initi
attempt
measur
directli
plasma
healthi
individu
unsuccess
moreov
circul
enzymat
activ
also
shown
low
even
undetect
anim
physiolog
condit
interestingli
patholog
state
human
ischem
heart
diseas
heart
failur
diabet
accompani
vascular
complic
well
rodent
model
diabet
circul
activ
augment
studi
patient
connect
tissu
diseas
contrast
report
antibodi
plasma
reduc
enzymat
activ
intrigu
observ
human
plasma
may
inhibit
enzymat
activ
made
base
incub
purifi
recombin
human
plasma
find
suggest
presenc
small
molecular
endogen
inhibitor
human
plasma
consist
robert
et
al
show
small
subset
patient
ckd
subgroup
activ
unprocess
plasma
markedli
lower
plasma
sampl
undergon
extract
process
remov
endogen
inhibitor
one
wonder
whether
process
hemodialysi
could
alter
level
inhibitor
plasma
owe
small
molecular
size
studi
dialysi
procedur
could
inform
regard
studi
robert
et
al
sampl
patient
hemodialysi
collect
prior
commenc
dialysi
middl
dialysi
day
week
remov
inhibitor
dialysi
procedur
howev
could
increas
plasma
activ
opposit
observ
dialysi
patient
result
studi
therefor
interpret
signifi
extract
endogen
inhibitor
dialysi
caus
reduc
plasma
activ
possibl
smallmolecular
inhibitor
might
form
complex
protein
therebi
evad
extract
dialysi
need
consid
plasma
inhibitor
inde
play
role
question
remain
caus
observ
reduct
plasma
activ
patient
esrd
undergo
dialysi
sourc
circul
healthi
individu
ckd
patient
clear
releas
kidney
possibl
level
activ
found
higher
mous
kidney
cortex
heart
urinari
activ
higher
urin
plasma
mechan
reach
circul
releas
plasma
well
understood
requir
examin
propos
solubl
lack
cytosol
transmembran
domain
aris
proteolyt
shed
membranebound
enzym
nevertheless
conceiv
fulllength
membranebound
also
releas
plasma
especi
diseas
state
associ
tissu
damag
myocardi
infarct
cell
cultur
experi
shed
solubl
stimul
disintegrin
metalloproteinas
inhibit
upon
interact
calmodulin
unlik
ace
endotheli
enzym
normal
express
minim
express
endotheli
layer
possibl
howev
patholog
condit
may
aberr
neoexpress
endotheli
cell
abnorm
express
endotheli
protein
could
shed
circul
could
sourc
increas
plasma
activ
certain
condit
myocardi
infarct
kidney
diseas
diabet
studi
knowledg
examin
plasma
possibl
pathway
calmodulin
might
involv
modul
releas
enzym
circul
gene
locat
chromosom
x
possibl
differ
plasma
activ
sex
examin
robert
et
al
multivari
analysi
male
femal
separ
predictor
plasma
activ
patient
undergo
dialysi
appear
differ
sex
male
plasma
activ
strongli
associ
bnp
increas
left
ventricular
hypertrophi
systol
dysfunct
femal
patient
undergo
hemodialysi
show
signific
associ
diabet
postdialysi
systol
blood
pressur
whether
associ
pathogen
therapeut
implic
await
examin
moreov
author
found
femal
hemodialysi
patient
compar
male
counterpart
lower
plasma
activ
analog
trend
lower
plasma
activ
femal
group
observ
kidney
transplant
patient
similar
recent
find
soler
et
al
found
plasma
activ
significantli
lower
femal
transplant
patient
compar
male
summari
articl
robert
et
al
suggest
patient
ckd
plasma
activ
increas
wherea
patient
esrd
undergo
dialysi
contrast
plasma
activ
reduc
compar
predialysi
ckd
patient
whether
plasma
inde
alter
ckd
patient
need
confirm
studi
includ
contemporari
measur
healthi
control
subject
moreov
longitudin
followup
ckd
cohort
would
ideal
monitor
activ
renal
function
declin
time
sever
question
remain
unansw
mechan
drive
circul
diseas
state
regardless
mechan
reduct
plasma
activ
report
esrd
patient
treat
dialysi
particularli
femal
subject
could
limit
ang
ii
degrad
lead
increas
level
peptid
could
contribut
high
preval
hypertens
cardiovascular
morbid
afflict
dialysi
popul
grant
support
niddk
content
articl
sole
respons
author
necessarili
repres
offici
view
nation
institut
health
none
declar
